Expression of angiogenic markers in the peripheral blood of patients with advanced breast cancer treated with weekly docetaxel

Anticancer Research

Volumn 32, Issue 10, 2012, Pages 4569-4580

  Korantzis, Ippokratis ^a   Kalogeras, Konstantine T ^a,b   Papaxoinis, George ^c   Kotoula, Vassiliki ^a   Koutras, Angelos ^d   Soupos, Nikolaos ^e   Papakostas, Pavlos ^c   Dionysopoulos, Dimitrios ^a   Samantas, Epaminontas ^f   Christodoulou, Christos ^g   Linardou, Helena ^g   Pectasides, Dimitrios ^c   Fountzilas, George ^a  

^a ARISTOTLE UNIVERSITY OF THESSALONIKI   (Greece)

^b Hellenic Cooperative Oncology Group   (Greece)

^c HIPPOKRATION HOSPITAL   (Greece)

^d UNIVERSITY OF PATRAS   (Greece)

^e UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^f AGII ANARGIRI CANCER HOSPITAL   (Greece)

^g METROPOLITAN HOSPITAL   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; DEXAMETHASONE; DIMETINDENE; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXEMESTANE; GONADORELIN DERIVATIVE; INTERLEUKIN 8; MESSENGER RNA; RANITIDINE; TAMOXIFEN; TRANSFORMING GROWTH FACTOR BETA1; TRASTUZUMAB;

ADULT; AGED; ANTIANGIOGENIC ACTIVITY; ARTICLE; BLOOD; BLOOD SAMPLING; BONE METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; EDEMA; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW UP; HUMAN; HUMAN TISSUE; IN VIVO STUDY; MAJOR CLINICAL STUDY; METRONOMIC DRUG ADMINISTRATION; MULTIPLE CYCLE TREATMENT; MULTIVARIATE ANALYSIS; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROPORTIONAL HAZARDS MODEL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; QUANTITATIVE ASSAY; RANK SUM TEST; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; STATISTICAL SIGNIFICANCE; TREATMENT RESPONSE;

AGED; AGED, 80 AND OVER; ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; BREAST NEOPLASMS; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERLEUKIN-8; MIDDLE AGED; NEOPLASMS, CYSTIC, MUCINOUS, AND SEROUS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTOR, ERBB-2; SEVERITY OF ILLNESS INDEX; TAXOIDS; TRANSFORMING GROWTH FACTOR BETA1; TUMOR MARKERS, BIOLOGICAL;

EID: 84867796107     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (56)

1. Mauri D, Kamposioras K, Tsali L, Bristianou M, Valachis A, Karathanasi I, Georgiou C, and Polyzos NP: Overall survival benefit for weekly vs. three-weekly taxanes regimens in advanced breast cancer: A meta-analysis. Cancer Treat Rev 36: 69-74, 2010.
2. Tabernero J, Climent MA, Lluch A, Albanell J, Vermorken JB, Barnadas A, Antón A, Laurent C, Mayordomo JI, Estaun N, Losa I, Guillem V, Garcia-Conde J, Tisaire JL and Baselga J: A multicentre, randomised phase II study of weekly or 3-weekly docetaxel in patients with metastatic breast cancer. Ann Oncol 15: 1358-1365, 2004. (Pubitemid 39295024)
3. Rivera E, Mejia JA, Arun BK, Adinin RB, Walters RS, Brewster A, Broglio KR, Yin G, Esmaeli B, Hortobagyi GN and Valero V: Phase 3 study comparing the use of docetaxel on an every-3-week versus weekly schedule in the treatment of metastatic breast cancer. Cancer 112: 1455-1461, 2008. (Pubitemid 351459423)
4. Sparano JA, Wang M, Martino S, Jones V, Perez EA, Saphner T, Wolff AC, Sledge GW Jr., Wood WC and Davidson NE: Weekly paclitaxel in the adjuvant treatment of breast cancer. N Engl J Med 358: 1663-1671, 2008. (Pubitemid 351549913)
5. Eniu A, Palmierin FM and Perez EA: Weekly administration of docetaxel and paclitaxel in metastatic or advanced breast cancer. Oncologist 10: 665-685, 2005. (Pubitemid 41567278)
6. Jones SE, Erban J, Overmoyer B, Budd GT, Hutchins L, Lower E, Laufman L, Sundaram S, Urba WJ, Pritchard KI, Mennel R, Richards D, Olsen S, Meyers ML and Ravdin PM: Randomized phase III study of docetaxel compared with paclitaxel in metastatic breast cancer. J Clin Oncol 23: 5542-5551, 2005.
7. Kamat AA, Kim TJ, Landen CN Jr, Lu C, Han LY, Lin YG, Merritt WM, Thaker PH, Gershenson DM, Bischoff FZ, Heymach JV, Jaffe RB, Coleman RL and Sood AK: Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res 67: 281-288, 2007. (Pubitemid 46142786)
8. Benelli R, Monteghirfo S, Balbi C, Barboro P and Ferrari N: Novel antivascular efficacy of metronomic docetaxel therapy in prostate cancer: hnRNP K as a player. Int J Cancer 124: 2989-2996, 2009.
9. Miller K, Wang M, Gralow J, Dickler M, Cobleigh M, Perez EA, Shenkier T, Cella D and Davidson NE: Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 357: 2666-2676, 2007.
10. Miles DW, Chan A, Dirix LY, Cortés J, Pivot X, Tomczak P, Delozier T, Sohn JH, Provencher L, Puglisi F, Harbeck N, Steger GG, Schneeweiss A, Wardley AM, Chlistalla A and Romieu G: Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol 28: 3239-3247, 2010.
11. Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol 5: 649-655, 1982. (Pubitemid 13149996)
12. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M and Clark GM: Statistics Subcommittee of the NCI-EORTC Working Group on Cancer Diagnostics. Reporting recommendations for tumour MARKer prognostic studies (REMARK). Eur J Cancer 41: 1690-1696, 2005.
13. Pectasides D, Papaxoinis G, Kotoula V, Fountzilas H, Korantzis I, Koutras A, Dimopoulos AM, Papakostas P, Aravantinos G, Varthalitis I, Kosmidis P, Skarlos D, Bournakis E, Bafaloukos D, Kalofonos HP, Kalogeras KT and Fountzilas G: Expression of angiogenic markers in the peripheral blood of docetaxel-treated advanced breast cancer patients: a Hellenic Cooperative Oncology Group (HeCOG) study. Oncol Rep 27: 216-224, 2012.
14. Gullick WJ, Love SB, Wright C, Barnes DM, Gusterson B, Harris AL and Altman DG: c-erbB-2 protein overexpression in breast cancer is a risk factor in patients with involved and uninvolved lymph nodes. Br J Cancer 63: 434-438, 1991.
15. Gusterson BA, Gelber RD, Goldhirsch A, Price KN, Save- Soderborgh J, Anbazhagan R, Styles J, Rudenstam CM, Golouh R and Reed R: Prognostic importance of c-erb-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 10: 1049-1056, 1992.
16. Eccles SA: The role of c-erbB-2/HER2/neu in breast cancer progression and metastasis. J Mammary Gland Biol Neoplasia 6: 393-406, 2001.
17. Asgeirsson KS, Agrawal A, Allen C, Hitch A, Ellis IO, Chapman C, Cheung KL and Robertson JF: Serum epidermal growth factor receptor and HER2 expression in primary and metastatic breast cancer patients. Breast Cancer Res 9: R75, 2007.
18. Baskic D, Ristic P, Pavlovic S and Arsenijevic N: HER2 and CA 15-3 in breast cancer patients. J BUON 9: 289-294, 2004. (Pubitemid 40360805)
19. Finn RS, Gagnon R, Di Leo A, Press MF, Arbushites M and Koehler M: Prognostic and predictive value of HER2 extracellular domain in metastatic breast cancer treated with lapatinib and paclitaxel in a randomized phase III study. J Clin Oncol 27: 5552-5558, 2009.
20. Bramwell VH, Doig GS, Tuck AB, Wilson SM, Tonkin KS, Tomiak A, Perera F, Vandenberg TA and Chambers AF: Changes over time of extracellular domain of HER2 (ECD/HER2) serum levels have prognostic value in metastatic breast cancer. Breast Cancer Res Treat 114: 503-511, 2009.
21. Leary AF, Hanna WM, van de Vijver MJ, Penault-Llorca F, Ruschoff J, Osamura RY, Bilous M and Dowsett M: Value and limitations of measuring HER2-Extracellular Domain in the serum of breast cancer patients. J Clin Oncol 27: 1694-1705, 2009.
22. Sorensen BS, Mortensen LS, Andersen J and Nexo E: Circulating HER2 DNA after trastuzumab treatment predicts survival and response in breast cancer. Anticancer Res 30: 2463-2468, 2010.
23. Cuadros M, Talavera P, Lopez FJ, Garcia-Perez I, Blanco A and Concha A: Real-time RT-PCR analysis for evaluating the Her2/neu status in breast cancer. Pathobiology 77: 38-45, 2010.
24. Varga Z and Mallon E: Histology and Immunophenotype of Invasive Lobular Breast Cancer. Daily Practice and Pitfalls. Breast Dis 30: 15-19, 2008.
25. Weigelt B, Geyer FC, Natrajan R, Lopez-Garcia MA, Ahmad AS, Savage K, Kreike B and Reis-Filho JS: The molecular underpinning of lobular histological growth pattern: a genomewide transcriptomic analysis of invasive lobular carcinomas and grade- and molecular subtype-matched invasive ductal carcinomas of no special type. J Pathol 220: 45-57, 2010.
26. Laughner E, Taghavi P, Chiles K, Mahon PC and Semenza GL: HER2 (neu) signalling increases the rate of hypoxia-inducible factor 1alpha (HIF-1alpha) synthesis: Novel mechanism for HIF-1-mediated vascular endothelial growth factor expression. Mol Cell Biol 21: 3995-4004, 2001. (Pubitemid 32476461)
27. Finkenzelle G, Weindel K, Zimmermann W, Westin G and Marme D: Activated Neu/ErbB-2 induces expression of the vascular endothelial growth factor gene by functional activation of the transcription factor Sp 1. Angiogenesis 7: 59-68, 2004. (Pubitemid 39127772)
28. Miller LJ, Kurtzman SH, Wanq Y, Anderson KH, Lindquist RR and Kreutzer DL: Expression of Interleukin-8 Receptors on Tumor Cells and Vascular Endothelial Cells in Human Breast Cancer Tissue. Anticancer Res 18: 77-82, 1998.
29. Snoussi K, Mahfoudh W, Bouaouina N, Fekih M, Khairi H, Helal AN and Chouchane L: Combined effects of IL-8 and CXCR2 genepolymorphisms on breast cancer susceptibility and aggressiveness. BMC Cancer 10: 283, 2010.
30. Belperio JA: CXC chemokines in angiogenesis. J Leukocyte Biol 68: 1-8, 2000.
31. Rofstad EK and Halsor EF: Hypoxia-associated spontaneous pulmonary metastasis in human melanoma xenografts: involvement of microvascular hot spots induced in hypoxic foci by interleukin 8. Br J Cancer 86: 301-308, 2002. (Pubitemid 34185162)
32. Ahmed Ol, Adel AM, Diab DR and Gobran NS: Prognostic value of serum level of interleukin-6 and interleukin-8 in metastatic breast cancer patients. Egypt J Immunol 13: 61-68, 2006.
33. Benoy IH, Salgado R, Van Dam P, Geboers K, Van Marck E, Scharpe S, Vermeulen PB and Dirix LY: Increased serum interleukin-8 in patients with early and metastatic breast cancer correlates with early dissemination and survival. Clin Cancer Res 10: 7157-7162, 2004. (Pubitemid 39487700)
34. Derin D, Soydinc HO, Guney N, Tas F, Camlica H, Duranyildiz D, Yasasever V and Topuz E: Serum IL-8 and IL-12 levels in breast cancer. Med Oncol 24: 163-168, 2007. (Pubitemid 350135966)
35. Lin Y, Huang R, Chen L, Li S, Shi Q, Jordan C and Huang RP: Identification of Interleukin-8 as Estrogen Receptor-Regulated Factor Involved in Breast Cancer Invasion and Angiogenesis by Protein Arrays. Int J Cancer 109: 507-515, 2004. (Pubitemid 38339640)
36. Freund A, Jolivel V, Durand S, Kersual N, Chalbos D, Chavey C, Vignon F and Lazennec G: Mechanisms underlying differential expression of interleukin-8 in breast cancer cells. Oncogene 23: 6105-6114, 2004. (Pubitemid 39178863)
37. Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S and Morishita Y: Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res 17: 695-699, 1997. (Pubitemid 27105552)
38. Kozlowski L, Zakrzewska I, Tokajuk P and Wojtukiewicz MZ: Concentration of interleukin-6 (IL-6), interleukin-8 (IL-8) and interleukin-10 (IL-10) in blood serum of breast cancer patients. Annates Academiae Medicae Bialostocensis 48: 82-84, 2003.
39. White CM, Martin BK, Lee LF, Haskill JS and Ting JP: Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes and breast cancer cells. Cancer Immunol Immunother 46: 104-112, 1998. (Pubitemid 28177485)
40. Muraoka-Cook RS, Dumont N and Arteaga CL: Dual role of transforming growth factor beta in mammary tumorigenesis and metastatic progression. Clin Cancer Res 11: 937-943, 2005.
41. Landmark-Høyvik H, Dumeaux V, Reinertsen KV, Edvardsen H, Fosså SD and Børresen-Dale AL: Blood gene expression profiling of breast cancer survivors experiencing fibrosis. Int J Radiat Oncol Biol Phys 79: 875-883, 2011.
42. Kulasekaran P, Scavone CA, Rogers DS, Arenberg DA, Thannickal VJ and Horowitz JC: Endothelin-1 and transforming growth factor-beta1 independently induce fibroblast resistance to apoptosis via AKT activation. Am J Respir Cell Mol Biol 41: 484-493, 2009.
43. Lebrect A, Grimm C, Euller G, Ludwig E, Ulbrich E, Lantzsch T, Hefler L and Koelbl H: Transforming growth factor beta 1 serum levels in patients with preinvasive and invasive lesions of the breast. Int J Biol Markers 19: 236-239, 2004. (Pubitemid 39406246)
44. Soufla G, Porichis F, Sourvinos G, Vassilaros S and Spandidos DA: Transcriptional deregulation of VEGF, FGF2, TGF-β1, 2, 3 and cognate receptors in breast tumorigenesis, Cancer Lett 235: 100-113, 2006.
45. Fenig E, Kanfi Y, Wang Q, Beery E, Livnat T, Wasserman L, Lilling G, Yahalom J, Wieder R and Nordenberg J: Role of TGF-b in the growth inhibition of human breast cancer cells by fibroblast growth factor. Breast Cancer Res Treat 70: 27-37, 2001. (Pubitemid 33105100)
46. Bierie B and Moses HL: TGFb: the molecular Jekyll and Hyde of cancer. Tumor Microenvironment 6: 506-520, 2006.
47. Buck MB and Knabbe C: TGF-Beta Signaling in Breast Cancer. Ann NY Acad Sci 1089: 119-126, 2006. (Pubitemid 47092079)
48. Barthelemy-Brichant N, David JL, BosqueeL, Bury T, Seidel L, Albert A, Bartsch P, Baugnet-Mahieu L and Deneufbourg JM: Increased TGFbeta plasma level in patients with lung cancer: potential mechanisms. Europ J Clin Invest 32: 193-198, 2002. (Pubitemid 36216604)
49. Barcellos-Hoff MH and Akhurst RJ: Transforming growth factor-β in breast cancer: too much, too late. Breast Cancer Res 11: 202, 2009.
50. Ivanovic V, Demajo M, Krtolica M, Krajnovic M, Konstantinovic M, Baltic V, Stojiljkkovic B, Breberina M, Neskovic-Konstantinovic Z, Nikolic- Vukosavljevic D and Dimitrijevic B: Elevated plasma TGF-beta1 levels correlate with decreased survival of metastatic breast cancer patients. Clin Chim Acta 371: 191-193, 2006. (Pubitemid 44162899)
51. Grau AM, Wen W, Ramroopsingh DS, Gao YT, Zi J, Cai Q, Shu XO and Zheng W: Circulating transforming growth factor-beta-1 and breast cancer prognosis: results from the Shanghai Breast Cancer Study. Breast Cancer Res Treat 112: 335-341, 2008.
52. Sheen-Chen SM, Chen HS, Sheen CW, Eng HL and Chen WJ: Serum levels of transforming growth factor beta1 in patients with breast cancer. Arch Surg 136: 937-940, 2001.
53. Chod J, Zavadova E, Halaska MJ, Strnad P, Fucikova T and Rob L: Preoperative transforming growth factor-beta 1 (TGF-beta 1) plasma levels in operable breast cancer patients. Eur J Gynaecol Oncol 29: 613-616, 2008.
54. Walker RA and Dearing SJ: Transforming growth factor beta 1 in ductal carcinoma in situ and invasive carcinomas of the breast. Eur J Cancer 28: 641-644, 1992.
55. Pasche B and Yi N: Candidate gene association studies: successes and failures. Curr Opin Genet Dev 20: 257-261, 2010.
56. Biswas S, Criswell TL, Wang SE and Arteaga CL: Inhibition of Transforming Growth Factor-b Signaling in Human Cancer: Targeting a Tumor Suppressor Network as a Therapeutic Strategy. Clin Cancer Res 12: 4142-4146, 2006.